Commentary on the Puli Pharmaceuticals (300630) incident: US influenza is showing an upward trend, and prioseltamivir has been approved for listing by the FDA
Pulley Pharmaceuticals (300630): Gross margin is under short-term pressure and there is more momentum for internationalization
Puli Pharmaceuticals (300630): Product structure and consolidation affect gross margin, and expect new products to gain strength one after another
Pulley Pharmaceuticals (300630): Costs, Expenses, and Prices Affect Gross Margin New Product Layout is worth looking forward to
Puli Pharmaceuticals (300630): Expecting new momentum during the variety switching period
Puli Pharmaceuticals (300630): Injections go overseas to accelerate API layout highlights continue
Pulley Pharmaceuticals (300630) incident review: Pfizer injection factory affected by the disaster, domestic injections are expected to go overseas at an accelerated pace
Pulley Pharmaceuticals (300630): Accumulate upward and wait for the inflection point
Pulley Pharmaceuticals (300630) Company Review: Steady Growth in Performance and Continued Advancement Overseas
Pulley Pharmaceuticals (300630): Performance grew steadily on a high base in line with expectations
Pulley Pharmaceuticals (300630): Revenue and profit hit record highs in a single quarter, and domestic and foreign injection doses are worth looking forward to
Pulley Pharmaceuticals (300630): Steady Growth, Accelerated Registration
Pulley Pharmaceuticals (300630): Gradual release of production capacity and acceleration of product registration
Pulley Pharmaceutical (300630): Steady growth in performance and domestic injection volume are worth looking forward to
Puli Pharmaceutical (300630) semi-annual report 2022 comments: the performance is in line with expectations and the approval of domestic and foreign products is expected to promote sustained and rapid growth.
Puli Pharmaceutical (300630): business in line with expectations of internationalization and vertical integration
Puli Pharmaceutical (300630): lansoprazole for injection passes consistency evaluation
Puli Pharmaceutical (300630) comments: Gadolinium meglumine gadolinate DMF has received the contrast medium and then the next city
Puli Pharmaceutical (300630) announcement comments: Iopamol is approved to be listed in the Netherlands to enter the 10 billion contrast medium market
Puli Pharmaceutical (300630): high growth in Quarterly report of Rapid release of overseas injections
No Data